Clinical trials: Body Weight Changes
Weight Loss
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type…
- Trial name
- NCT07868835
- Testing
- VK2735
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Weight Loss
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
- Trial name
- NCT07868939
- Testing
- VK2735 Oral
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Body Weight Changes
Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
- Trial name
- NCT03509545
- Testing
- CHF Patients: ER Torsemide 40 mg, CHF Patients: Furosemide 40 mg
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Obesity, Weight Change Trajectory
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both…
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Trial name
- REMAIN-1 (NCT06484114)
- Testing
- Revita Duodenal Mucosal Resurfacing (DMR)
- Where
- 32 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Fractyl Health Inc.
Hunger, Weight Change
Hunger Perception and Weight-Related Outcomes Following Use of a Leptin-Supporting Dietary Supplement
This study evaluates changes in hunger perception and body composition-related measures following daily use of a commercially available dietary supplement formulated to support leptin-related metabolic signaling.
- Trial name
- NCT07442864
- Testing
- Leptin Balance Formula
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Efforia, Inc
Weight Loss, Obesity
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
This is a Phase 2 randomized, double-blind, placebo-controlled, parallel arm study of NA-931 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
- Conditions
- Weight Loss, Obesity, Body Weight, Body Weight Changes
- Trial name
- NCT06564753
- Testing
- NA-931, dose 1, daily and orally, NA-931, dose2, daily and orally, NA-931 dose 3, daily and orally
- Where
- 5 sites in Australia
- Volunteers
- 126 people
- Sponsor
- Biomed Industries, Inc.
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma
Weight Change, Body, Type 2 Diabetes
Digitally-Enabled Weight Management Program on T2DM
The study (known as clinical audit in UK) will observe and report on a digitally-enabled structured weight management program including use of a meal replacement on clinical and economic outcomes for community-dwelling adults…
- Trial name
- NCT05483140
- Testing
- Option 1, Option 2, Option 3
- Where
- 4 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- Abbott Nutrition
Body Weight Changes, Metabolic Syndrome
Evaluation the Effect of AKK Formula on Intestinal Microbiota Regulation and Body Composition
The AKK formula, a prebiotic blend, can effectively promote the proliferation of A. muciniphila. In this study, we attempt to explore the clinical efficacy of AKK formula for A. muciniphila proliferation and weight management.
- Trial name
- NCT06132269
- Testing
- AKK formula prebiotic sachet
- Where
- Taiwan
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Overweight and Obesity, Body Weight Changes
Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management
PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120).
- Conditions
- Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise
- Trial name
- PHAEOSOL-ONE (NCT04761406)
- Testing
- Phaeosol group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Microphyt
Body Weight Changes
Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)
Protocol Number: VNI/121/TrimRox: A unique stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical formulation, TrimROXTM, has been developed in a cGMP and NSF-certified manufacturing facility that is CFR-111 A compliant as…
- Trial name
- VNI (NCT05283525)
- Testing
- Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches, Oxygen Saturation, Total Blood Chemistry
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Victory Nutrition International, Inc.
Damage Muscle, Body Weight Changes
Chronic Study on Body Composition, Training, Performance, and Recovery
The chronic phase of the study will evaluate the effects of pre-exercise and post-exercise ingestion of a multi-ingredient supplement on adaptations to a 6-week exercise program consisting of both resistance training and high…
- Conditions
- Damage Muscle, Body Weight Changes, Performance Enhancing Product Use
- Trial name
- NCT04230824
- Testing
- Pre-workout plus and Protein recovery plus, 6-week resistance training program
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Body Weight Changes
Cryolipolysis Induced Gluteal Fat Change
There was no difference in efficacy in removal of local fat on thigh by cryolipolysis through Zeltiq machine. Cryolipolysis was found to be safe for 12 week clinical trial.
- Trial name
- NCT04568187
- Testing
- zeltiq
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Wonik Trade Company, Korea
Change in Total Body Fat Mass Percentage Loss Versus Body Weight
Evaluation of Sinetrol® Xpur in Fat Mass Reduction on Overweight and Obese Subjects
This study aims to evaluate effects of a 16-week supplementation with a polyphenol rich extract, Sinetrol® Xpur, on fat mass accumulation and body weight management improvement.Subjects were overweight or obese and received…
- Trial name
- NCT04149158
- Testing
- Sinetrol® Xpur
- Where
- Spain
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Fytexia
Obesity, Obesity, Abdominal
Impact of the Use of FeelWell™ Compression Garment on Individuals With a BMI ≥35
To assess the effect of wearing a custom-fitted, FDA-registered, Class I device, compression garment (Obesinov, S.A.R.L.) by an individual with a BMI ≥ 35 on his/her day-to-day quality of life over a period of one year.
- Conditions
- Obesity, Obesity, Abdominal, Mobility Limitation, Quality of Life
- Trial name
- NCT03798873
- Testing
- FeelWell™ Compression garment, Increase Mobility
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Feelwell Compression
Body Weight Changes
Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain
The purpose of this study is to assess the effects of repeated periods of modified fasting in support of healthy weight management and prevention of weight gain over the winter holiday period (mid-November to early January) in…
- Trial name
- NCT03372109
- Testing
- Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Supplement Formulators, Inc.
HIV Infections, Cachexia
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion…
- Conditions
- HIV Infections, Cachexia, Anorexia, AIDS Wasting Syndrome
- Trial name
- NCT00637572
- Testing
- Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL
- Where
- 12 sites in United States, India and 1 more
- Volunteers
- 63 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Body Weight Change, Schizophrenia
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
- Conditions
- Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00095524
- Testing
- Aripiprazole
- Where
- 32 sites in United States, Brazil and 1 more
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.